AcrySof ReSTOR to hit US shelves

Article

Alcon has received FDA approval for the AcrySof ReSTOR intraocular lens (IOL) for the correction of aphakia following cataract surgery in patients with or without presbyopia.

Alcon has received FDA approval for the AcrySof ReSTOR intraocular lens (IOL) for the correction of aphakia following cataract surgery in patients with or without presbyopia.

The apodized, diffractive aspheric IOL is the only FDA approved presbyopia-correcting lens that incorporates aspheric optics into its design.

Alcon will commence a phased launch of AcrySof ReSTOR after necessary consignment quantities are established, with full distribution expected by the middle of the year.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.